tyrosine kinase inhibitors

News

TKI Discontinuation Associated With Improved PROs in CML

12/03/2020

Journal of Clinical Pathways

Research Reports

Trend in TKI Use, Adherence, and Switching Patterns in Patients With CML: Before and After the Availability of Generic Imatinib

08/19/2020

Gary H. Lyman , MD, MPH, FASCO, FRCP, FACP;

David R. Doody , MS;

Shasank Chennupati , PharmD, MPH;

Eric J. Chow , MD, MPH;

Lena E. Winestone , MD, MSHP;

Henry J. Henk , PhD;

Pamela Morin , MBA;

Jennifer J. Wilkes , MD, MSCE;

Abstract: The therapeutic landscape for chronic myeloid leukemia (CML) has evolved substantially over the past decade, most notably with the introduction of second- and third-generation tyrosine kinase inhibitors...

...

08/19/2020

Journal of Clinical Pathways

Research in Review

Novel Therapy Plus Gemcitabine Does Not Improve OS in Pancreatic Cancer

04/11/2017

JCP Editors

A new tyrosine kinase inhibitor (TKI) in combination with gemcitabine does not improve overall survival (OS) any more than gemcitabine alone for patients with advanced pancreatic cancer, according to research...

A new...

04/11/2017

Journal of Clinical Pathways

Research in Review

Novel TKI Therapy Plus Gemcitabine Does Not Improve OS in Pancreatic Cancer

03/09/2017

JCP Editors

A new...

03/09/2017

Journal of Clinical Pathways

Research in Review

TKI Discontinuation Improves Remission Rates for Patients With CML

03/03/2017

JCP Editors

Patients with chronic myeloid leukemia (CML) who discontinued treatment with second-generation tyrosine kinase inhibitors (TKIs) benefited from significant treatment-free remission rates, according to research...

...

03/03/2017

Journal of Clinical Pathways

Research in Review

Most Cost-Effective Sequence of TKIs for Treatment of GISTs Identified

01/10/2017

JCP Editors

The best potential strategy involving tyrosine kinase inhibitors (TKIs) for the treatment of gastrointestinal stromal tumors (GISTs) has been identified, according to new research published in Clinical Drug...

The...

01/10/2017

Journal of Clinical Pathways

Research in Review

Varying Toxicities Between EGFR-TKIs for Treatment of NSCLC

12/29/2016

JCP Editors

Varying degrees of toxicity risks between different epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) can help inform treatment decisions for individual patients with non-small cell lung...

...

12/29/2016

Journal of Clinical Pathways

Research Reports

Cost-Effectiveness of Afatinib Versus Erlotinib in the First-line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With EGFR Exon 19 Deletion Mutations

05/06/2016

Rakesh Luthra , MS;

Jonathan Graham , BS;

Stephanie Earnshaw , PhD;

Rohit Borker , PhD;

Jonathan Lim , BS, MS, MSc;

Abstract: A decision model was developed to compare the cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) with epidermal growth...

...

05/06/2016

Journal of Clinical Pathways